ArticleJournal of thoracic disease2025
Risk and prognostic patterns of viral-associated invasive pulmonary aspergillosis: impact of corticosteroid and antibiotic exposure in non-neutropenic hosts.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of different therapies on invasive pulmonary aspergillosis in patients with severe fever and thrombocytopenia syndrome: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- The clinical application of metagenomic next-generation sequencing for invasive pulmonary aspergillosis in neutropenic patients: a multicenter retrospective study in the ICU.Frontiers in cellular and infection microbiology · 2026Article
- Comparative clinical features and outcomes of invasive pulmonary aspergillosis following influenzaFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive pulmonary aspergillosis (IPA), which is traditionally linked to immunocompromised states, has been increasingly observed in non-neutropenic patients with severe viral pneumonias, especially those caused by the 2009 novel influenza A (H1N1) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The influence of corticosteroid and antibiotic exposure on IPA risk and outcomes in this population remains poorly defined. This study aimed to investigate the impact of corticosteroid and antibiotic exposure on the risk and outcomes of IPA in non-neutropenic patients with viral pneumonias. Methods: A retrospective study was conducted for 234 non-neutropenic adults with laboratory-confirmed H1N1, coronavirus disease 2019 (COVID-19), or co-infection. The clinical, laboratory, and therapeutic data were examined for associations with IPA incidence and mortality. Restricted cubic spline models were employed to assess the non-linear dose-response relationships. Survival differences were evaluated using Kaplan-Meier (KM) curves. Results: IPA occurred in 152 patients (65.00%), with the highest incidence in co-infection (89.00%), followed by H1N1 (67.00%) and COVID-19 (42.00%). IPA was associated to higher corticosteroid and antibiotic exposure, diabetes, chronic lung disease, and intensive care unit (ICU) admission. Co-infection correlated to greater drug exposure, higher Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, and increased mortality (36.80% Conclusions: Both corticosteroid and antibiotic exposures are independently associated to increased risk and mortality of IPA, in a non-linear, dose-dependent manner. These findings emphasize the importance of judicious therapeutic use and early risk stratification to mitigate IPA burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.